X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SENTI-202 is an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies including acute myeloid leukemia.
Lead Product(s): SENTI-202
Therapeutic Area: Oncology Product Name: SENTI-202
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
SENTI-202 is a potential first-in-class off-the-shelf CAR-NK cell therapy using Logic Gated Gene Circuits to selectively target cancer cells while sparing healthy bone marrow cells. It is being evaluated for the treatment of acute myeloid leukemia (AML).
Lead Product(s): SENTI-202
Therapeutic Area: Oncology Product Name: SENTI-202
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Under the collaboration, Celest will lead clinical development for the advancement of SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of GPC3 expressing tumors.
Lead Product(s): SENTI-301A
Therapeutic Area: Oncology Product Name: SENTI-301A
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Celest Therapeutics
Deal Size: $156.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 06, 2023
Details:
Under the partnership, GeneFab will support manufacturing of Senti’s chimeric antigen receptor natural killer (CAR-NK) medicines pipeline, including SENTI-202, for the treatment of CD33 and/or FLT3 expressing hematologic malignancies, such as AML and MDS.
Lead Product(s): SENTI-202
Therapeutic Area: Oncology Product Name: SENTI-202
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: GeneFab
Deal Size: $38.0 million Upfront Cash: $38.0 million
Deal Type: Acquisition August 10, 2023
Details:
Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expressing AML cell lines while protecting healthy cells.
Lead Product(s): SENTI-202
Therapeutic Area: Oncology Product Name: SENTI-202
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
SENTI-401 is designed to incorporate logic gating to target and kill CEA-expressing tumor cells, while preventing the killing of CEA-expressing healthy epithelial cells for the treatment of colorectal cancer (CRC).
Lead Product(s): SENTI-401
Therapeutic Area: Oncology Product Name: SENTI-401
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Senti’s existing investors continue to support the mission of engineering gene circuits with programmable logic in cell and gene therapies, and progress in advancing multiple oncology programs including SENTI-202, towards the clinic.
Lead Product(s): SENTI-202
Therapeutic Area: Oncology Product Name: SENTI-202
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Leaps by Bayer
Deal Size: $5.2 million Upfront Cash: Undisclosed
Deal Type: Financing May 24, 2022
Details:
SENTI-202 oral presentation details systematic optimization of Logic Gating Gene Circuit technology in allogeneic CAR-NK cells to more precisely target tumor cells in acute myeloid leukemia, while sparing healthy cells.
Lead Product(s): SENTI-202
Therapeutic Area: Oncology Product Name: SENTI-202
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
SENTI-202 is designed to target and eliminate acute myeloid leukemia cells while sparing healthy bone marrow. Our vision is a potential medicine that does not rely on an invasive bone marrow transplant.
Lead Product(s): SENTI-202
Therapeutic Area: Oncology Product Name: SENTI-202
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Senti Bio’s gene circuit technology is being applied in the design of multiple product candidates including SENTI-202 for the acute myeloid leukemia (AML), SENTI-301 for hepatocellular carcinoma (HCC) and SENTI-401 for treatment of colorectal cancer (CRC).
Lead Product(s): SENTI-202
Therapeutic Area: Oncology Product Name: SENTI-202
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
